Magnesium levels and outcome after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.
Linus AngenendtIsabel HilgefortJan-Henrik MikeschBernhard SchlüterWolfgang E BerdelGeorg LenzMatthias StelljesChristoph SchliemannPublished in: Annals of hematology (2020)
Low intake of magnesium has been associated with the occurrence of lymphomas and decreased magnesium levels suppress the cytotoxic function of T cells and natural killer cells in patients with "X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection, and neoplasia" (XMEN) syndrome. These cell types are also important mediators of immune-mediated effects after allogeneic hematopoietic stem cell transplantation. Here, we show that high posttransplant magnesium levels independently associate with a lower incidence of relapse, a higher risk of acute graft-versus-host disease, and a higher non-relapse mortality in 368 patients with acute myeloid leukemia from our center. Magnesium serum levels might impact on donor-cell-mediated immune responses in acute myeloid leukemia.
Keyphrases
- allogeneic hematopoietic stem cell transplantation
- acute myeloid leukemia
- epstein barr virus
- acute lymphoblastic leukemia
- immune response
- single cell
- diffuse large b cell lymphoma
- risk factors
- risk assessment
- cardiovascular events
- mesenchymal stem cells
- cardiovascular disease
- toll like receptor
- dendritic cells
- bone marrow
- case report
- respiratory failure
- drug induced
- body mass index